Selling Your Veterinary Practice to Western Veterinary Partners: A Vet’s 2026 Guide

By Melani Seymour, co-founder, Transitions Elite.

Key takeaways

• Western Veterinary Partners is one of the fastest-scaling national veterinary platforms in the United States — headquartered in Denver, Colorado, founded in 2019, and grown to more than 325 hospitals across roughly 39 states on a regional-cluster model.
• Tyree & D’Angelo Partners (TDP), a Chicago-based private equity firm, owns Western and in November 2025 launched a single-asset continuation fund anchored by HarbourVest to fund further expansion per public disclosures.
• Local brand preservation and aligned equity for affiliated doctors are defining features of Western’s veterinarian-centric model per Western company materials. Practices typically keep their name, signage, and customer-facing identity.
• The seller’s core question with Western is “what does it mean to join a platform growing this fast?” Rapid scale brings operational momentum and capital, and it also means the network at signing may look different by the time an earnout or equity buyout matures — which is exactly where the negotiation leverage sits.
• The most reliable way to know what Western — or any major buyer — would actually pay for your specific practice is to run a structured competitive process. We call ours the Elite Selling System: we hand-select and vet every buyer who gets to bid, the way a doorman with a velvet rope lets in only the right people, then run a private bidding window inside that vetted group. Western is invited inside that rope on practices that fit their regional clusters, and when they bid against a curated group of qualified competitors the number is reliably very different from a direct, single-bidder conversation.

When a vet asks me about Western Veterinary Partners, the conversation almost always starts with some version of the same question. “These people are growing incredibly fast — what does it actually mean to join a platform moving at that speed?” That instinct is the right one to follow. The pace of Western’s growth is the single most important thing to understand about them as a buyer.

Founded in 2019, Western reached more than 325 hospitals across roughly 39 states in just a few years. That is one of the steepest growth curves in the entire US veterinary consolidator pool.

A platform expanding that fast has real advantages and real things a seller needs to pin down before signing.

So that’s the through-line of every Western conversation. Not “what kind of company is this,” but “what does it mean for my practice and my post-sale life to join a network scaling this aggressively.” Both the upside and the things to negotiate flow from that one fact.

What follows is the same picture I’d lay out over dinner if a vet handed me a Western offer and asked what to do with it. Who Western is, how the rapid-growth model shapes the deal, what the affiliation approach means for sellers in 2026, where the negotiation leverage actually sits, and how to think about Western against the rest of the US veterinary buyer pool in a properly run process.

Quick facts on Western Veterinary Partners

Western Veterinary Partners is a private equity-backed veterinary support organization — a company that provides non-clinical business support to affiliated veterinary practices while the doctors retain their clinical work. Western is headquartered in Denver, Colorado, at 210 University Boulevard, and was founded in 2019 per company materials.

In a few short years Western grew to more than 325 hospitals across roughly 39 states, primarily concentrated in the western and central United States. That footprint makes it one of the fastest-scaling national veterinary platforms in the country, and Western was named to the 2024 Inc. 5000 list of fast-growing companies.

The growth is built on a regional-cluster model. Rather than scatter single acquisitions across the map, Western adds density in markets where it already operates, which makes shared support, recruiting reach, and referral networks easier to deliver. The platform describes itself as veterinarian-centric, emphasizing clinical mentorship, continuing education, and aligned equity ownership for affiliated doctors per Western company materials.

Western is owned by Tyree & D’Angelo Partners (TDP), a Chicago-based private equity firm with a buy-and-build strategy. In November 2025, TDP announced a single-asset continuation fund for Western anchored by HarbourVest — a structure that lets a private equity sponsor extend its ownership of a strong portfolio company while bringing in fresh capital, explicitly to fund Western’s continued organic growth and acquisitions per the TDP and HarbourVest announcements.

Western has also drawn financing and minority capital from lenders and investors including TPG Twin Brook and Apogem Capital per public disclosures.

The most important practical fact for a seller evaluating Western. The platform is scaling at a pace that means the network you join at signing may look materially different by the time your earnout or equity buyout matures. That is structurally different from a slow-and-steady platform, and the implications run in both directions — capital and momentum on one side, a moving operational target on the other.

What Western Veterinary Partners actually pays for veterinary practices in 2026

The consistent pattern we see. When a multi-doctor practice receives a direct offer from any major buyer’s acquisition team — Western included — the offer reflects the leverage the buyer perceives in the conversation. A single bidder facing no visible competition has no structural reason to lead with their strongest cash percentage, tightest earnout protections, most flexible clinical-autonomy language, or most explicit brand-preservation guarantees in the first conversation.

Inside a properly structured competitive process, where the buyer knows other qualified bidders are underwriting the same practice in parallel, those dimensions tend to move, sometimes meaningfully. The pattern is not unique to Western.

It is the basic dynamic of how every major buyer in this market calibrates an offer to the room.

Western does not publish a standard price sheet for any specific practice profile. Per industry M&A commentary (Octus, Capstone Partners, 2025-2026), competitive outcomes for strong multi-doctor general practices in the $2 million-plus revenue range tend to land in the low-teens EBITDA range across the major buyer pool.

EBITDA is what your practice earns in pure operating profit, before taxes and accounting choices, and the multiple is the multiplier buyers apply to that earnings number to set the price.

The actual number for any specific practice depends heavily on whether other buyers are at the table and on the specific profile of the practice. With Western, geographic fit carries extra weight. A practice that adds density inside an existing Western regional cluster can be strategically more valuable to them than the same practice in a market where they have no presence. Western participates in this competitive band when they bid on qualifying practices, with the specific offer negotiated case by case under confidentiality.

For larger multi-location groups ($10 million-plus revenue, $2 million-plus EBITDA), the multiple range typically extends higher than for single-location practices, with deal sizes scaling into the eight-figure-plus range. Western’s well-capitalized position — reinforced by the 2025 continuation fund — means the platform has the capacity to bid for larger groups when the practice profile and geography match.

For practices below the $2 million revenue threshold or single-doctor practices, the buyer pool generally shifts toward smaller regional groups and individual buyers, though a sub-threshold practice that fills a strategic gap in a Western cluster can still draw interest. Western’s footprint and cluster logic mean geographic fit can matter as much as raw size in whether a practice is on their radar.

The cash-at-close reality

For a well-capitalized, fast-growing platform like Western, the cash-at-close component of any offer is unlikely to be where the platform underperforms competitive expectations. Per industry M&A commentary across the major buyer pool (Dechert LLP, Holland & Knight, Capstone Partners 2025-2026), the typical offer structure allocates the majority of total deal value to cash at close, with the remainder split among earnout, rollover or aligned equity, and occasional seller notes.

Cash at close is the guaranteed portion of the price wired to you at the closing table, and Western’s specific allocation on any given deal is negotiated case by case.

Where the rapid-growth profile shows up in the cash-at-close conversation is in the platform’s appetite and capital position. A consolidator in aggressive expansion mode backed by a fresh continuation fund generally has the dry powder to support strong cash percentages on practices it genuinely wants for its clusters.

That is good news for the cash side of a Western offer.

The flip side a seller should hold in mind is what gets deferred. The non-cash components — earnout and aligned equity — are precisely the pieces whose ultimate value depends on how the fast-scaling network performs over the next several years.

That makes the structure and protections on those deferred pieces the part of a Western deal that deserves the closest attention, which is exactly where the next sections focus.

A note on deal structure types in the current market

The broader US veterinary M&A market has shifted measurably toward partnership, joint-venture, and aligned-equity structures over the past 18 months per MB Law Firm’s 2025 healthcare M&A commentary. In these structures the buyer acquires a majority stake, the seller retains a minority slice as equity, and a contractual put/call mechanism defines the buyout date and formula price for the retained equity.

Rollover equity means keeping a slice of ownership in the new entity instead of taking all cash at close.

Western’s own materials emphasize aligned equity ownership for affiliated veterinarians as a distinctive feature of its model. That fits the broader market direction and is one reason the equity terms deserve real scrutiny in a Western deal.

The specific posture — how much equity, at what valuation, with what liquidity timing — is determined case by case under confidentiality and is not publicly enumerated.

What can be said with confidence is that the value of any aligned-equity or rollover slice is a bet on the platform’s trajectory. For a platform growing as fast as Western, that bet has genuine upside and genuine variables, which makes the valuation mechanics, the liquidity windows, and the governance rights the pieces to negotiate carefully.

Our PE pricing guide covers the structure-by-structure comparison in depth.

How Western Veterinary Partners’ acquisition team operates

Western’s corporate-development effort is built around the regional-cluster strategy. The team’s sourcing has historically emphasized practices that add density in markets where Western already operates per company materials — recruiting reach, shared support, and referral networks are all easier to deliver when a new affiliation sits inside an existing Western cluster.

The team works the standard mix of sourcing channels: direct outreach to owners identified through industry data and broker relationships, participation in structured competitive sale processes run by qualified sell-side advisors, and inbound inquiries from owners reaching out independently. A platform acquiring at Western’s pace runs a high-volume, well-resourced pipeline.

A practical implication for sellers. A fast-moving acquirer can also move fast on a seller’s timeline, which is a real convenience, but speed cuts both ways. The same momentum that lets Western close quickly can create pressure to sign a standard template before a seller has tested the market.

The acquisition team tends to engage more substantively, and compete harder on terms, when the materials they receive reflect a sophisticated sell-side process rather than a casual one-on-one conversation. That isn’t unique to Western, but it means a properly run competitive process is worth materially more than a seller facing a fast, friendly direct offer might assume.

How Western Veterinary Partners integrates the practices it acquires

Western’s integration model is operationally supportive but identity-conservative — the platform takes on the non-clinical back-office while leaving the practice’s clinical work and local brand with the doctors.

Local brand preservation. Per Western company materials, the platform emphasizes preserving each practice’s culture, name, signage, and local reputation in its community. The integration is focused on non-clinical support rather than brand consolidation.

This contrasts structurally with Mars-affiliated entities, which more commonly transition acquired practices to a Mars-network brand over time.

Non-clinical back-office support. Per Western company materials, the platform provides payables and cash management, inventory, payroll, collections, human resources, marketing, recruitment, IT, and back-office administration. Because Western is scaling rapidly on a regional-cluster model, that support is delivered through regional teams that build density in existing markets.

Recruiting and continuing education. A fast-growing, veterinarian-centric platform invests heavily in recruiting reach and clinical development, and Western emphasizes mentorship and continuing education for affiliated doctors per company materials. For a practice struggling to recruit associates in a tight labor market, that reach can be a genuine draw.

Aligned equity and doctor relationships. Western’s materials emphasize aligned equity ownership for affiliated veterinarians as a distinguishing feature. Per industry M&A commentary on private equity-backed veterinary acquirers, selling owners commonly stay on in a continuing clinical or medical-leadership role for a multi-year post-close period, typically 3 to 5 years, with compensation structured as base salary plus production bonus.

Western’s specific post-sale employment and equity terms for any given deal are negotiated case by case under the definitive purchase agreement.

The rapid-scale integration caveat. A platform integrating at Western’s pace is, by definition, integrating a lot of practices at once. The operational support a seller is promised at signing has to scale alongside the network, and the regional team supporting a cluster can change as that cluster grows.

None of that is a knock on Western; it is the structural reality of any fast-scaling platform, and it is why the integration commitments worth having are the ones written into the agreement rather than described in a pitch.

Western Veterinary Partners’ recent activity in 2025-2026

Western enters 2026 as one of the most active acquirers in the US veterinary buyer pool. Capstone Partners‘ April 2026 Pet Sector M&A Update documents the broader sector acceleration heading into Q1 2026, with both PE-backed and strategic acquirers running active pipelines, and Octus’s 2025-2026 sector coverage notes growing dispersion across veterinary roll-ups and increasing pressure on support organizations generally.

The defining recent event for Western was the November 2025 single-asset continuation fund led by Tyree & D’Angelo Partners and anchored by HarbourVest, structured specifically to fund continued organic growth and acquisitions per the announcements. That capital event signals a platform planning to keep scaling rather than slowing down.

Specific acquisition counts are not itemized by Western in real time.

The practical takeaway for an owner receiving 2026 Western outreach: this is a buyer running a sustained, well-funded acquisition program at one of the fastest paces in the sector. The implications of that pace — the capital and momentum on one side, the moving operational target on the other — are the lens through which the offer in your hand should be evaluated.

Have an offer from Western Veterinary Partners? Get a Free Practice Value Estimate — send us the offer and we’ll decompose the terms, identify what’s typically negotiable, and project what your practice would likely clear in a structured competitive process with the broader qualified buyer pool. No upfront cost, no obligation.

How Western Veterinary Partners compares to the other major buyers

If you’re considering Western, you’re probably comparing them implicitly to the other major buyers who would compete for your practice. Here’s how Western stacks up across the dimensions that matter.

Versus Mars Veterinary Health (VCA, BluePearl, Banfield). Mars is the strategic family-owned exception in the US veterinary buyer pool per Mars company disclosures, distinguishing it from Western’s PE-backed structure. The brand-handling difference is significant — Western’s local-brand-preservation approach contrasts with VCA’s historical brand-consolidation pattern under the VCA name.

Both Mars-affiliated entities and Western may compete for qualifying practices in a structured sale process. Our Mars Veterinary Health buyer profile covers the Mars-specific dimensions in depth.

Versus NVA (JAB Holdings). NVA is owned by JAB Holdings, a privately held long-hold investment vehicle distinguishable from PE-fund-cycle ownership. Both NVA and Western preserve local practice branding per their respective company materials.

The key structural difference is the ownership horizon and growth posture — JAB’s long-hold stance versus Western’s fast-scaling PE-fund model create different equity-timing dynamics. Our NVA buyer profile walks through the NVA-specific dimensions.

Versus AmeriVet Veterinary Partners. AmeriVet has publicly emphasized partnership and JV structures as a distinguishing feature, while Western emphasizes aligned equity within its affiliation model. Both preserve local brand identity per their respective company materials.

The choice often comes down to which equity structure and growth profile fit the seller’s goals. Our AmeriVet buyer profile covers the partnership-model dimensions.

Versus VetCor (Harvest Partners). VetCor is one of the longest-tenured PE-backed platforms, with a refined integration playbook built over more than two decades. Western is closer to the opposite end of the spectrum — newer and scaling far faster.

A seller choosing between them is often weighing institutional depth and predictability (VetCor) against momentum, capital, and growth upside (Western). Our VetCor buyer profile covers the longevity dimension.

Versus Mission Pet Health and the partnership-emphasis buyers. Mission Pet Health, the post-merger entity formed from SVP and MVP per the July 2025 Mission Pet Health press release, is concentrated in the Sun Belt and Southeast — a footprint that overlaps with parts of Western’s central-US density in some markets. Both may compete for qualifying practices in a structured sale process.

Versus the smaller and newer PE-backed groups (Thrive Pet Healthcare, Alliance Animal Health, Rarebreed, Heartland, VPP, others). Each has its own integration philosophy and target profile. Smaller and newer groups sometimes pay more aggressively for practices that fill specific geographic gaps.

The right way to evaluate which buyer pays most is to put all of them in a competitive process and let them surface their best offers in parallel.

What to negotiate before signing with Western Veterinary Partners

Six priorities when negotiating with Western’s acquisition team, with the deferred-consideration protections as the highest-leverage category given the platform’s rapid-growth profile.

Earnout protective provisions (highest priority). An earnout is the part of the sale price paid later, only if the practice hits agreed performance targets after closing. On a fast-scaling platform, central decisions — procurement, vendor consolidation, operational standardization — can happen quickly and shift practice-level EBITDA in either direction during the earnout window.

Negotiate: no major operational changes without seller consent during the earnout period; a working capital floor; an explicit prohibition on shifting central services costs from other Western practices onto yours; a clear definition of what counts in the EBITDA calculation at the earnout date.

Aligned-equity and rollover terms. Western emphasizes aligned equity, and the value of that slice is a bet on a fast-growing platform’s trajectory. Negotiate the valuation methodology in writing, defined liquidity windows tied to specific milestones, governance and information rights, and anti-dilution provisions — especially important on a platform raising and deploying capital rapidly, where dilution risk is real.

Cash at close percentage. Push for higher cash percentages on the acquired stake. Every dollar shifted from contingent to guaranteed is money you keep regardless of how the platform performs.

Western’s well-capitalized position generally supports flexibility on this dimension when the process is competitive.

Non-compete scope. Non-competes commonly run several years and cover a defined geographic radius for all veterinary work. Negotiate shorter duration (1 to 2 years), a tighter radius (5 to 10 miles), or a carve-out for specific modalities if you might continue clinical work post-employment.

Post-sale clinical autonomy. A veterinarian-centric model is a strong starting point, but “centric” in marketing is not the same as a contractual carve-out. Negotiate explicit language preserving your clinical autonomy — you make medicine decisions, not the regional team — and a clear definition of which decisions stay with you versus migrating to Western’s regional structure as it scales.

Brand and support commitments in writing. Western’s materials emphasize brand preservation and robust non-clinical support. Negotiate those into the definitive purchase agreement — practice name, signage, website, and the specific support commitments — rather than relying on pitch-stage descriptions, because on a fast-growing platform the regional support structure can evolve over the years your earnout and equity are maturing.

The fast-growth question, in depth

For sellers evaluating Western specifically, the most useful frame is to think carefully about what it means to join a platform scaling this aggressively. The growth is the headline, and the seller’s job is to capture the upside while protecting against the variables.

The case for joining a fast-growing platform. A consolidator expanding at Western’s pace brings real advantages, and they compound:

• A well-funded acquisition program backed by a fresh continuation fund generally supports strong cash-at-close numbers on practices it wants
• Aligned equity in a fast-growing platform carries genuine upside if the trajectory holds
• Heavy investment in recruiting reach can solve an associate-hiring problem that an independent practice struggles with alone
• Regional-cluster density delivers shared support, referral networks, and purchasing leverage
• Momentum and capital mean the platform can move quickly on a seller’s timeline

The case for the fast-growth profile as a negotiation surface. The same speed creates variables a seller should negotiate against:

• The network you join at signing may look materially different by the time your earnout or equity buyout matures
• A platform integrating many practices at once means the operational support promised at signing has to scale alongside the network
• The regional team supporting your cluster can change as that cluster grows
• Aligned-equity value depends on a trajectory that, while strong to date, is a forward-looking bet
• A fast-moving acquirer can create pressure to sign a standard template before the market has been tested

The balance between these is exactly what gets negotiated in the definitive purchase agreement. Sellers who go in with a refined sell-side process — and other qualified bidders at the table — consistently land more favorable positions on both sides of that balance than sellers who engage in a one-on-one conversation.

Should I take a Western offer or run a competitive process?

For Western specifically, the value of the competitive process shows up in two places. First on the headline economics, because a fast-growing platform that wants a practice for its cluster will compete hard on price when it knows other qualified buyers are underwriting the same practice.

Second, and just as important, on the deferred-consideration protections — the earnout clauses, the equity valuation and liquidity mechanics, the clinical-autonomy carve-outs — that determine whether the fast-scaling trajectory works in the seller’s favor or against it.

The mechanical reason is the same as for any major buyer. Without competition, no buyer has incentive to soften the pre-set defaults in its standard template or to put forward its strongest number.

With competition, every term becomes negotiable because every bidder knows the seller has alternatives.

Western participates in well-run competitive processes when invited. The Western-specific dimensions — the earnout protections against rapid central-cost changes, the aligned-equity valuation and anti-dilution language, the clinical-autonomy carve-outs against an evolving regional structure — get sharper attention from the Western team when they know other qualified buyers are at the table on the same practice in the same window.

What our Elite Selling System actually does

For a Western-affiliated transaction, our process is tuned to the rapid-growth profile — because the seller’s real exposure lives in the deferred pieces whose value depends on how the fast-scaling network performs.

Phase one — the deferred-consideration audit. Before any bidder packet goes out, we deconstruct what a Western standard template typically defers and at what risk. How is the earnout protected against central-cost shifts on a fast-growing platform?

How is the aligned equity valued, and what liquidity and anti-dilution terms attach to it? What clinical-autonomy and support commitments are written down versus merely described?

This audit identifies the leverage points before the competitive process opens.

Phase two — the bidder mix. From the 42-plus named veterinary consolidators TE actively tracks, we invite only the ones that legitimately compete with Western for this specific practice. The growth-and-capital competitors (other well-funded scaling platforms), the brand-preservation buyers (NVA, AmeriVet, and the smaller PE-backed pool with explicit brand-preservation positioning), the institutional-depth alternative (VetCor), and the family-owned strategic option (Mars, where the practice fits its criteria) each compete on a dimension a Western-minded seller cares about.

The right mix is typically 5 to 7 invited bidders, each genuinely competing.

Phase three — the term-by-term comparison. Bidders return their full term sheets, not just the headline numbers. The seller sees side-by-side comparisons across cash at close, earnout structure and protective provisions, aligned-equity or rollover terms, non-compete scope, post-sale role, brand and support commitments, and regional decision rights.

The seller chooses on the dimensions that matter — sometimes the fast-growing platform with the most aligned-equity upside (Western), sometimes the platform with the deepest institutional track record, sometimes the highest headline number.

The economic result holds across deal types: practices in the qualifying revenue band that run our process consistently clear materially better total economic outcomes — typically multiple seven figures, sometimes more — than the same practice would have cleared by signing the original direct term sheet without exploring the field.

Closing thought

The honest read on Western Veterinary Partners: it is one of the fastest-scaling national veterinary platforms in the United States, well-capitalized, veterinarian-centric, and committed to local brand preservation per its own materials. For the right seller — especially one whose practice adds density to a Western regional cluster — that growth and momentum can translate into a strong offer and a genuine aligned-equity upside.

What separates a well-negotiated Western outcome from a mediocre one is how the deferred pieces are protected against the realities of rapid scale. The earnout provisions, the equity valuation and liquidity mechanics, the clinical-autonomy carve-outs, the written support and brand commitments.

Those terms determine whether the fast-growth trajectory works for the seller or quietly works against them across the post-close years.

If you’ve received a Western offer, or if Western’s acquisition team has reached out to start the conversation, the highest-leverage move is to understand how the rest of the field would structure the same practice before committing to anything. Get a Free Practice Value Estimate and we’ll lay out the same term-by-term comparison we would for a client across a dinner table.

Sources

Industry M&A research and valuation data

1. Capstone Partners. Pet Sector M&A Update — April 2026. Capstone Partners industry research.
2. Octus. Private-Credit Exposure to Veterinary Rollups Shows Growing Dispersion; VSOs Under Increasing Pressure. Octus credit research and industry commentary, 2025.
3. Dechert LLP. Healthcare M&A: 2025-2026 Trends and Outlook. Dechert healthcare practice publications.
4. Holland & Knight. Healthcare Private Equity 2025-2026 Commentary. Holland & Knight healthcare practice publications.
5. MB Law Firm. 2025 Healthcare M&A Trends — Joint Venture and Partnership Structures. MB Law Firm healthcare publications.

Western Veterinary Partners and parent company materials

6. Western Veterinary Partners. About Western Veterinary Partners and US network footprint. Western company materials, 2024-2026.
7. Tyree & D’Angelo Partners. Tyree & D’Angelo Partners Announces Single-Asset Continuation Fund of Western Veterinary Partners. TDP announcement, November 2025.
8. Tyree & D’Angelo Partners. Minority Growth Investment in Western Veterinary Partners; investment profile. TDP company materials.
9. Inc. Western Veterinary Partners — 2024 Inc. 5000 honoree. Inc. 5000 company profile.

Veterinary practice operations, benchmarks, and profession data

10. iVET360. State of the Veterinary Industry — 2026 Industry Report. iVET360 industry research.
11. American Veterinary Medical Association (AVMA). 2026 AVMA Veterinary Economic Report. AVMA economic research.